<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04540796</url>
  </required_header>
  <id_info>
    <org_study_id>CR108882</org_study_id>
    <secondary_id>2020-001183-29</secondary_id>
    <secondary_id>75348780LYM1001</secondary_id>
    <nct_id>NCT04540796</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize safety and to determine the putative recommended&#xD;
      Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with&#xD;
      relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)&#xD;
      in Part A and to further characterize the safety at the RP2D(s) in Part B.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      B-cell lymphoid malignancies include CLL and NHL and are defined by clonal populations of&#xD;
      B-lymphocytes expressing identical surface antigens. CD22 is a surface protein specifically&#xD;
      expressed on B-lymphocytes and is expressed in B-lymphocytic malignancies. It is known to&#xD;
      negatively regulate the B-cell receptor via its cytosolic immunoreceptor tyrosine-based&#xD;
      inhibitory motifs. JNJ-75348780 is a novel human bispecific antibody that recognizes the CD3&#xD;
      antigen on T-lymphocytes and the CD22 antigen on mature and malignant B-lymphocytes.&#xD;
      JNJ-75348780 is hypothesized to lead to cytotoxicity, T-cell activation and induction of&#xD;
      cytokines upon engagement of CD3 on T-cells and CD22 on malignant B-lymphocytes. The study&#xD;
      consists of screening phase, treatment phase and post-treatment phase. The total study&#xD;
      duration will be up to 2.7 years. Efficacy assessments will include radiographic image&#xD;
      assessments, positron emission tomography scan, bone marrow assessment, endoscopy or&#xD;
      colonoscopy, physical examinations. Safety will be monitored throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">May 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 11, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and Part B: Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A and Part B: Number of Participants with AEs by Severity</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A and Part B: Number of Participants with Dose-Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Number of participants with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-75348780</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>AUCtau is the measure of the serum drug concentration from time zero to end of dosing interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Serum Concentration (Cmax) of JNJ-75348780</measure>
    <time_frame>Predose, 48 hours postdose (up to 2.7 years)</time_frame>
    <description>Cmax is the maximum observed serum concentration of JNJ-75348780.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Observed Serum Concentration (Cmin) of JNJ-75348780</measure>
    <time_frame>Predose, 48 hours postdose (up to 2.7 years)</time_frame>
    <description>Cmin is the minimum observed serum concentration of JNJ-75348780.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>ORR is defined as the percentage of participants who achieve a complete response (CR) and partial response (PR) or better according to the revised response criteria for malignant lymphoma, the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) response criteria and International Workshop for Waldenstrom Macroglobulinemia (IWWM) response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) Rate</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>CR rate is defined as the percentage of participants who achieve a best response of CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>TTR is defined for participants who achieved PR or CR as the time from the first dose of study drug to first response of PR or CR according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 2.7 years</time_frame>
    <description>DOR is defined for participants who achieved PR or CR as the time between the date of initial documentation of PR or CR to the date of either the first documented evidence of disease progression or death according to the revised response criteria for malignant lymphoma, iwCLL response criteria and IWWM response criteria.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Leukemia, Lymphocytic, Chronic, B-Cell</condition>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive once weekly dose or may receive every 2 weeks (Q2W) administration of JNJ-75348780. The dose levels will be escalated sequentially based on the decisions of the Study Evaluation Team (SET), along with the potential exploration of other routes of administration and schedules, until one or more recommended Phase 2 Doses (RP2D) have been identified.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive JNJ-75348780 at one of the putative RP2Ds determined in Part A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-75348780</intervention_name>
    <description>Participants will receive JNJ-75348780 by subcutaneous (SC) administration.</description>
    <arm_group_label>Part A: Dose Escalation</arm_group_label>
    <arm_group_label>Part B: Cohort Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic documentation of disease: B-cell NHL or CLL requiring therapy; All&#xD;
             participants must have relapsed or refractory disease with no other approved therapies&#xD;
             available that would be more appropriate in the investigator's judgment.&#xD;
&#xD;
        B cell NHL as defined per the 2016 World Health Organization (WHO) classification: In&#xD;
        addition, the following disease-specific criteria outlined below must be met a) If diffuse&#xD;
        large B-cell lymphoma (DLBCL): received, or not eligible for high-dose chemotherapy and&#xD;
        autologous stem cell transplantation with curative intent, b) If follicular lymphoma (FL)/&#xD;
        marginal zone lymphoma (MZL) (except mucosa-associated lymphoid tissue [MALT]), or&#xD;
        Waldenstrom macroglobulinemia (WM): previously treated with a minimum of 2 prior lines of&#xD;
        systemic therapy, with at least 1 prior line containing an anti-CD20 antibody, c) If mantle&#xD;
        cell lymphoma (MCL): previously treated with at least 1 prior line of systemic therapy&#xD;
        containing an anti-CD20 antibody. CLL or small lymphocytic lymphoma (SLL): relapsed or&#xD;
        refractory with at least 2 prior lines of therapy to include a bruton tyrosine kinase&#xD;
        inhibitor (BTKi) and/or a B-cell lymphoma (BCL)2 inhibitor, if eligible. For Part B:&#xD;
        participants must have measurable disease as defined by the appropriate disease response&#xD;
        criteria&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status Grade of 0 or 1&#xD;
&#xD;
          -  Cardiac parameters within the following range: corrected QT interval (QTc intervals&#xD;
             corrected using Fridericia's formula [QTcF]) less than or equal to (&lt;=) 480&#xD;
             milliseconds (ms) based on the average of triplicate assessments performed no more&#xD;
             than 5 (plus minus [+ -] 3) minutes apart&#xD;
&#xD;
          -  Women of childbearing potential must have a negative highly sensitive serum pregnancy&#xD;
             test (Beta human chorionic gonadotropin) at screening and prior to the first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Women must be: a) not of childbearing potential, b) of childbearing potential and&#xD;
             practicing a highly effective, preferably user independent method of contraception&#xD;
             (failure rate of less than (&lt;) 1 percent (%) per year when used consistently and&#xD;
             correctly) and agrees to remain on a highly effective method while receiving study&#xD;
             drug and until 90 days after last dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known active central nervous system (CNS) involvement with lymphoma&#xD;
&#xD;
          -  Prior solid-organ transplantation&#xD;
&#xD;
          -  Either of the following: a) received an autologous stem cell transplant &lt;=3 months&#xD;
             before the first dose of JNJ 75348780, b) prior treatment with allogenic stem cell&#xD;
             transplant &lt;= 6 months before the first dose of JNJ-75348780, or has evidence of graft&#xD;
             versus host disease that requires immunosuppressant therapy&#xD;
&#xD;
          -  Prior chemotherapy, targeted therapy, immunotherapy or radiotherapy (with the&#xD;
             exclusion of palliative radiation to limited sites that do not interfere with response&#xD;
             assessment based on a sufficient number of other sites), within 2 weeks before the&#xD;
             first administration of study drug. For investigational agents where the half-life is&#xD;
             known, there should be a treatment-free window of at least 2 weeks or 5 half-lives,&#xD;
             whichever is longer. For investigational agents with long half-lives a wash-out of 4&#xD;
             weeks is acceptable&#xD;
&#xD;
          -  Active autoimmune disease that requires systemic immunosuppressive medications&#xD;
             (example, chronic corticosteroid, methotrexate, or tacrolimus)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital Sydney</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - HÃ´pital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>NANTES Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>74047</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky MC</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Vall D'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Germans Trias I Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Univ. de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp. Clinico Univ. de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital, Kaohsiung</name>
      <address>
        <city>Kaohsiung County</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B9 5ST</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie Nhs Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospital NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108882</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson is available at www.janssen.com/clinicaltrials/ transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

